Results 21 to 30 of about 126,662 (215)

Clinically Significant Prostate Cancer Prediction Using Multimodal Deep Learning with Prostate-Specific Antigen Restriction

Current Oncology
Prostate cancer (PCa) is a clinically heterogeneous disease. Predicting clinically significant PCa with low–intermediate prostate-specific antigen (PSA), which often includes aggressive cancers, is imperative. This study evaluated the predictive accuracy
Hayato Takeda, Jun Akatsuka, Tomonari Kiriyama, Yuka Toyama, Yasushi Numata, Hiromu Morikawa, Kotaro Tsutsumi, Mami Takadate, Hiroya Hasegawa, Hikaru Mikami, Kotaro Obayashi, Yuki Endo, Takayuki Takahashi, Manabu Fukumoto, Ryuji Ohashi, Akira Shimizu, Go Kimura, Yukihiro Kondo, Yoichiro Yamamoto   +18 more
doaj   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Elucidating the need for prostate cancer risk calculators in conjunction with mpMRI in initial risk assessment before prostate biopsy at a tertiary prostate cancer center

BMC Urology
Objective Utilizing personalized risk assessment for clinically significant prostate cancer (csPCa) incorporating multiparametric magnetic resonance imaging (mpMRI) reduces biopsies and overdiagnosis.
Philipp Krausewitz, Thomas Büttner, Marthe von Danwitz, Richard Weiten, Alexander Cox, Niklas Klümper, Johannes Stein, Julian Luetkens, Glen Kristiansen, Manuel Ritter, Jörg Ellinger   +10 more
doaj   +1 more source

Usefulness of free PSA ratio to enhance detection of clinically significant prostate cancer in patients with PI-RADS<3 and PSA≤10

Prostate International
Background: The necessity of prostate biopsy in patients with a Prostate Imaging–Reporting and Data System (PI-RADS) score below 3 and prostate-specific antigen (PSA) levels of 4–10 ng/ml remains controversial. We tested the diagnostic performance of the
Ji Eun Heo, Hyun Ho Han, Won Sik Jang, Won Sik Ham, Woong Kyu Han, Young Deuk Choi, Jongsoo Lee   +6 more
doaj   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source

Value of machine learning-based transrectal multimodal ultrasound combined with PSA-related indicators in the diagnosis of clinically significant prostate cancer

Frontiers in Endocrinology, 2023
ObjectiveTo investigate the effect of transrectal multimodal ultrasound combined with serum prostate-specific antigen (PSA)-related indicators and machine learning for the diagnosis of clinically significant prostate cancer.MethodsBased on Gleason score ...
Maoliang Zhang, Yuanzhen Liu, Yuanzhen Liu, Yuanzhen Liu, Jincao Yao, Jincao Yao, Jincao Yao, Kai Wang, Jing Tu, Zhengbiao Hu, Yun Jin, Yue Du, Xingbo Sun, Liyu Chen, Liyu Chen, Zhengping Wang   +15 more
doaj   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Cognitive Targeted Prostate Biopsy Alone for Diagnosing Clinically Significant Prostate Cancer in Selected Biopsy-Naïve Patients: Results from a Retrospective Pilot Study

Diagnostics
(1) Background: To identify a particular setting of biopsy-naïve patients in which it would be reasonable to offer only cognitive targeted prostate biopsy (PBx) with a transrectal approach.
Michelangelo Olivetta, Celeste Manfredi, Lorenzo Spirito, Carmelo Quattrone, Francesco Bottone, Marco Stizzo, Ugo Amicuzi, Arturo Lecce, Andrea Rubinacci, Lorenzo Romano, Giampiero Della Rosa, Salvatore Papi, Simone Tammaro, Paola Coppola, Davide Arcaniolo, Ferdinando Fusco, Marco De Sio   +16 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Optimal PSA Threshold for Obtaining MRI-Fusion Biopsy in Biopsy-Naïve Patients

Prostate Cancer, 2021
Objective. The study investigates the prostate-specific antigen threshold for adding targeted, software-based, magnetic resonance imaging-ultrasound fusion biopsy during a standard 12-core biopsy in biopsy-naïve patients.
Luke L. Wang, Brandon L. Henslee, Peter B. Sam, Chad A. LaGrange, Shawna L. Boyle   +4 more
doaj   +1 more source